Sorana Segal-Maurer

Infectious Disease

5645 Main St
Flushing, NY 11355

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Treatment patterns, health care resource utilization, and costs of heavily treatment-experienced people with HIV in the United States.

Treatment patterns, health care resource utilization, and costs of heavily treatment-experienced people with HIV in the United States.

Journal: Journal of managed care & specialty pharmacy

Published: November 26, 2025

Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study.

Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study.

Journal: Open forum infectious diseases

Published: August 05, 2025

Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline.

Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline.

Journal: Open forum infectious diseases

Published: June 25, 2025

Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered.

Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered.

Journal: AIDS (London, England)

Published: November 15, 2024

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years.

Resistance Analyses in Heavily Treatment-Experienced People With HIV Treated With the Novel HIV Capsid Inhibitor Lenacapavir After 2 Years.

Journal: The Journal of infectious diseases

Published: October 10, 2024

Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1).

Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1).

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 28, 2024

Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial.

Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 17, 2024

Novel case of combination antibiotic therapy for treatment of a complicated polymicrobial urinary tract infection with one organism harboring a metallo-β-lactamase (MBL) in a pregnant patient.

Novel case of combination antibiotic therapy for treatment of a complicated polymicrobial urinary tract infection with one organism harboring a metallo-β-lactamase (MBL) in a pregnant patient.

Journal: IDCases

Published: October 04, 2023

A case of Lactobacillus jensenii associated native valve endocarditis.

A case of Lactobacillus jensenii associated native valve endocarditis.

Journal: IDCases

Published: April 19, 2023

Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.

Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.

Journal: The lancet. HIV

Published: February 02, 2023

Early Introduction and Community Transmission of SARS-CoV-2 Omicron Variant, New York, New York, USA.

Early Introduction and Community Transmission of SARS-CoV-2 Omicron Variant, New York, New York, USA.

Journal: Emerging infectious diseases

Published: January 24, 2023

Omadacycline for the treatment of Mycobacterium abscessus infections: Case series and review of the literature.

Omadacycline for the treatment of Mycobacterium abscessus infections: Case series and review of the literature.

Journal: IDCases

Published: January 12, 2023

Showing 1-12 of 34

Last Updated: 09/26/2026